The increasing worldwide prevalence of obesity has greatly affected care for people with type 2 diabetes. More precisely, >90% of people with diabetes have some degree of overweight or obesity (1). In addition to increased risk of cardiovascular and renal disease, obesity contributes to worsening of hyperglycemia and progression of prediabetes to type 2 diabetes.
The development of pharmacotherapy for the treatment of obesity has increased significantly in the past decade, especially with regard to incretin mimetics. This drug class has several advantages that make them highly desirable pharmacotherapy options for the treatment of obesity and diabetes, including high efficacy for weight loss, low risk of hypoglycemia, and reduction of cardiorenal disease risks. Until recently, drugs in this class focused on agonism of receptors for the single peptide hormone glucagon-like peptide 1 (GLP-1). The more recently developed drug tirzepatide combined GLP-1 receptor agonism with agonism of receptors for...
